WuXi PharmaTech COO Highlights Growth

WuXi PharmaTech plans to continue its growth by expanding into biotech, safety evaluation and manufacturing. In fact, to make the growth a reality, the company invests about $60 million each year in capital expenditures. "The majority of our clients are big international firms, with Pfizer and Merck ranking as the top two,” said Hu. “As business expands, we want to win more clients, big or small, and get more orders from current customers,” said Edward Hu, COO of the WuXi PharmaTech in a recent interview. More details... Stock Symbol: (NYSE: WX)